Taylor Schreiber to speak at the 2020 CD47/Sirp a Summit – March 18-19th in Boston

Shattuck Labs CSO and Co-Founder to give presentation: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity

For Agenda and Registration go to https://www.cd47sirpa.com/
Taylor Schreiber
Chief Scientific Officer
Shattuck Labs

Taylor  co-founded  Shattuck Labs  and currently serves  as Chief Scientific Officer  and is a member of the Board  of Directors. Taylor is the lead  inventor of Shattuck’s ARC technology  platform.

Prior  to Shattuck,  Taylor served as  Chief Scientific Officer  of Heat Biologics, Inc. where  he was a co-inventor of significant  elements of Heat’s ImPACT and ComPACT  technology platforms. He was also the co-inventor  of TNFRSF25 agonist technology developed by Pelican  Therapeutics, where he served as Chairman of the Scientific  Advisory Board. Taylor has numerous publications in the field  of tumor immunology and immunotherapy, spanning the subjects of cancer  vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated  immunosuppression and regulatory T cell biology. In 2008, Taylor received the  best overall research award at the National Student Research Forum and in 2011 he  was nominated as a Future Leader in Cancer Research by the American Association for  Cancer Research. Taylor  received  his M.D. and  Ph.D. degrees from  the Sheila and David  Fuente Program in Cancer  Biology at the University of  Miami Miller School of Medicine.  He received his B.A. in Biology from  Bucknell University.
He Beat Lymphoma at 31, While Pioneering Breakthroughs in Cancer Research

It looked like only good things were ahead of Taylor Schreiber in 2010. Schreiber had just finished his PhD in…

Read more
Shattuck Labs Poster Presentation - SITC 2018

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-FC-OX40L), For Cancer Immunotherapy

Read more